On November 19, 2018 Genomic Health, Inc. (NASDAQ: GHDX) reported that it will present results from two large studies of the Oncotype DX Breast Recurrence Score test at the 2018 San Antonio Breast Cancer Symposium (SABCS), which will be held December 4-8 (Press release, Genomic Health, NOV 19, 2018, View Source [SID1234531438]). The study findings reinforce the value of the Oncotype DX test in optimizing treatment and outcomes in patients with both node-negative and node-positive early-stage breast cancer. Presentations include:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Results from a large population-based clinical outcomes study based on the Surveillance, Epidemiology, and End Results (SEER) registry program of the National Cancer Institute (NCI), the premier source of cancer statistics in the United States. To provide long-term (nine years) real-world evidence for both prognosis and chemotherapy benefit, the study assessed breast cancer-specific survival in patients with node-negative and node-positive disease who were treated based on their Oncotype DX Breast Recurrence Score test results.
Analysis of 500 early-stage breast cancer patients age 40 or younger to further the understanding of the value of the Oncotype DX test in guiding chemotherapy treatment decisions. The analysis is based on a multi-center prospective cohort study led by Dana-Farber Cancer Institute investigators in Boston.
Complete results from both studies will be announced in accordance with the SABCS embargo policy. Following are details for the two poster presentations:
Abstract: P3-11-02Poster: Breast cancer specific mortality in patients with node-negative and node-positive breast cancer guided by the 21-gene assay: A SEER-genomic population-based studyAuthors: Hortobagyi GN, Shak S, Sledge GW Jr., Winer EP, Albain KS, Mamounas EP, Jakubowski DM, Petkov VI, Wolmark NLocation: Hall 1Date and Time: Thursday, December 6, 7-9 a.m. CST
Abstract: P2-08-07Poster: Prognostic impact of the 21-gene Recurrence Score assay among young women with node-negative and node-positive early-stage breast cancerAuthors: Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, Russell C, Winer EP, Partridge AHLocation: Hall 1Date and Time: Thursday, December 6, 7-9 a.m. CST
About Oncotype DX
The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company’s flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. With more than 950,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com or www.MyBreastCancerTreatment.org.